This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
by Zacks Equity Research
TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.
Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind
by Zacks Equity Research
Phibro (PAHC) input costs continue to be high as a result of sustained inflation.
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.
3 Medical Device Stocks With Potential to Fight Deflation Risk
by Indrajit Bandyopadhyay
Here we discuss three medical devices stocks, ABCM, ITGR and RXST, which have robust growth outlook in the long term. Betting on these stocks will help investors offset any potential deflationary risk.
Thermo Fisher (TMO) Completes the CorEvitas Acquisition
by Zacks Equity Research
Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.
Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.
Here's Why You Should Invest in Alcon (ALC) Stock Now
by Zacks Equity Research
Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.
Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.
Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.
QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.
Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise
by Zacks Equity Research
Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.
Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.
QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test
by Zacks Equity Research
QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.
Here's Why You Should Invest in Medtronic (MDT) Stock Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
by Zacks Equity Research
Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.
AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.
DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.
Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.